GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression

Sandra Baumgart, Nai Ming Chen, Jin San Zhang, Daniel D Billadeau, Irina N. Gaisina, Alan P. Kozikowski, Shiv K. Singh, Daniel Fink, Philipp Ströbel, Caroline Klindt, Lizhi Zhang, William R. Bamlet, Alexander Koenig, Elisabeth Hessmann, Thomas M. Gress, Volker Ellenrieder, Albrecht Neesse

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We aimed to investigate the mechanistic, functional, and therapeutic role of glycogen synthase kinase 3β (GSK-3β) in the regulation and activation of the proinflammatory oncogenic transcription factor nuclear factor of activated T cells (NFATc2) in pancreatic cancer. IHC, qPCR, immunoblotting, immunofluorescence microscopy, and proliferation assays were used to analyze mouse and human tissues and cell lines. Protein-protein interactions and promoter regulation were analyzed by coimmunoprecipitation, DNA pulldown, reporter, and ChIP assays. Preclinical assays were performed using a variety of pancreatic cancer cells lines, xenografts, and a genetically engineered mouse model (GEMM). GSK-3β-dependent SP2 phosphorylationmediates NFATc2 protein stability in the nucleus of pancreatic cancer cells stimulating pancreatic cancer growth. In addition to protein stabilization, GSK-3β also maintains NFATc2 activation through a distinct mechanism involving stabilization of NFATc2-STAT3 complexes independent of SP2 phosphorylation. For NFATc2-STAT3 complex formation, GSK-3β-mediated phosphorylation of STAT3 at Y705 is required to stimulate euchromatin formation of NFAT target promoters, such as cyclin-dependent kinase-6, which promotes tumor growth. Finally, preclinical experiments suggest that targeting the NFATc2-STAT3-GSK-3β module inhibits proliferation and tumor growth and interferes with inflammationinduced pancreatic cancer progression in KrasG12D mice. In conclusion, we describe a novel mechanism by which GSK-3b fine-tunes NFATc2 and STAT3 transcriptional networks to integrate upstream signaling events that govern pancreatic cancer progression and growth. Furthermore, the therapeutic potential of GSK-3β is demonstrated for the first time in a relevant Kras and inflammation-induced GEMM for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)491-502
Number of pages12
JournalMolecular Cancer Therapeutics
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Glycogen Synthase Kinase 3
Pancreatic Neoplasms
Inflammation
Growth
Cyclin-Dependent Kinase 6
Phosphorylation
Euchromatin
NFATC Transcription Factors
Cell Line
Proteins
Protein Stability
Gene Regulatory Networks
Fluorescence Microscopy
Immunoblotting
Heterografts
Neoplasms
Transcription Factors
DNA
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression. / Baumgart, Sandra; Chen, Nai Ming; Zhang, Jin San; Billadeau, Daniel D; Gaisina, Irina N.; Kozikowski, Alan P.; Singh, Shiv K.; Fink, Daniel; Ströbel, Philipp; Klindt, Caroline; Zhang, Lizhi; Bamlet, William R.; Koenig, Alexander; Hessmann, Elisabeth; Gress, Thomas M.; Ellenrieder, Volker; Neesse, Albrecht.

In: Molecular Cancer Therapeutics, Vol. 15, No. 3, 01.03.2016, p. 491-502.

Research output: Contribution to journalArticle

Baumgart, S, Chen, NM, Zhang, JS, Billadeau, DD, Gaisina, IN, Kozikowski, AP, Singh, SK, Fink, D, Ströbel, P, Klindt, C, Zhang, L, Bamlet, WR, Koenig, A, Hessmann, E, Gress, TM, Ellenrieder, V & Neesse, A 2016, 'GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression', Molecular Cancer Therapeutics, vol. 15, no. 3, pp. 491-502. https://doi.org/10.1158/1535-7163.MCT-15-0309
Baumgart, Sandra ; Chen, Nai Ming ; Zhang, Jin San ; Billadeau, Daniel D ; Gaisina, Irina N. ; Kozikowski, Alan P. ; Singh, Shiv K. ; Fink, Daniel ; Ströbel, Philipp ; Klindt, Caroline ; Zhang, Lizhi ; Bamlet, William R. ; Koenig, Alexander ; Hessmann, Elisabeth ; Gress, Thomas M. ; Ellenrieder, Volker ; Neesse, Albrecht. / GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression. In: Molecular Cancer Therapeutics. 2016 ; Vol. 15, No. 3. pp. 491-502.
@article{6fe18eae21bd4193be635d19412bd888,
title = "GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression",
abstract = "We aimed to investigate the mechanistic, functional, and therapeutic role of glycogen synthase kinase 3β (GSK-3β) in the regulation and activation of the proinflammatory oncogenic transcription factor nuclear factor of activated T cells (NFATc2) in pancreatic cancer. IHC, qPCR, immunoblotting, immunofluorescence microscopy, and proliferation assays were used to analyze mouse and human tissues and cell lines. Protein-protein interactions and promoter regulation were analyzed by coimmunoprecipitation, DNA pulldown, reporter, and ChIP assays. Preclinical assays were performed using a variety of pancreatic cancer cells lines, xenografts, and a genetically engineered mouse model (GEMM). GSK-3β-dependent SP2 phosphorylationmediates NFATc2 protein stability in the nucleus of pancreatic cancer cells stimulating pancreatic cancer growth. In addition to protein stabilization, GSK-3β also maintains NFATc2 activation through a distinct mechanism involving stabilization of NFATc2-STAT3 complexes independent of SP2 phosphorylation. For NFATc2-STAT3 complex formation, GSK-3β-mediated phosphorylation of STAT3 at Y705 is required to stimulate euchromatin formation of NFAT target promoters, such as cyclin-dependent kinase-6, which promotes tumor growth. Finally, preclinical experiments suggest that targeting the NFATc2-STAT3-GSK-3β module inhibits proliferation and tumor growth and interferes with inflammationinduced pancreatic cancer progression in KrasG12D mice. In conclusion, we describe a novel mechanism by which GSK-3b fine-tunes NFATc2 and STAT3 transcriptional networks to integrate upstream signaling events that govern pancreatic cancer progression and growth. Furthermore, the therapeutic potential of GSK-3β is demonstrated for the first time in a relevant Kras and inflammation-induced GEMM for pancreatic cancer.",
author = "Sandra Baumgart and Chen, {Nai Ming} and Zhang, {Jin San} and Billadeau, {Daniel D} and Gaisina, {Irina N.} and Kozikowski, {Alan P.} and Singh, {Shiv K.} and Daniel Fink and Philipp Str{\"o}bel and Caroline Klindt and Lizhi Zhang and Bamlet, {William R.} and Alexander Koenig and Elisabeth Hessmann and Gress, {Thomas M.} and Volker Ellenrieder and Albrecht Neesse",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0309",
language = "English (US)",
volume = "15",
pages = "491--502",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression

AU - Baumgart, Sandra

AU - Chen, Nai Ming

AU - Zhang, Jin San

AU - Billadeau, Daniel D

AU - Gaisina, Irina N.

AU - Kozikowski, Alan P.

AU - Singh, Shiv K.

AU - Fink, Daniel

AU - Ströbel, Philipp

AU - Klindt, Caroline

AU - Zhang, Lizhi

AU - Bamlet, William R.

AU - Koenig, Alexander

AU - Hessmann, Elisabeth

AU - Gress, Thomas M.

AU - Ellenrieder, Volker

AU - Neesse, Albrecht

PY - 2016/3/1

Y1 - 2016/3/1

N2 - We aimed to investigate the mechanistic, functional, and therapeutic role of glycogen synthase kinase 3β (GSK-3β) in the regulation and activation of the proinflammatory oncogenic transcription factor nuclear factor of activated T cells (NFATc2) in pancreatic cancer. IHC, qPCR, immunoblotting, immunofluorescence microscopy, and proliferation assays were used to analyze mouse and human tissues and cell lines. Protein-protein interactions and promoter regulation were analyzed by coimmunoprecipitation, DNA pulldown, reporter, and ChIP assays. Preclinical assays were performed using a variety of pancreatic cancer cells lines, xenografts, and a genetically engineered mouse model (GEMM). GSK-3β-dependent SP2 phosphorylationmediates NFATc2 protein stability in the nucleus of pancreatic cancer cells stimulating pancreatic cancer growth. In addition to protein stabilization, GSK-3β also maintains NFATc2 activation through a distinct mechanism involving stabilization of NFATc2-STAT3 complexes independent of SP2 phosphorylation. For NFATc2-STAT3 complex formation, GSK-3β-mediated phosphorylation of STAT3 at Y705 is required to stimulate euchromatin formation of NFAT target promoters, such as cyclin-dependent kinase-6, which promotes tumor growth. Finally, preclinical experiments suggest that targeting the NFATc2-STAT3-GSK-3β module inhibits proliferation and tumor growth and interferes with inflammationinduced pancreatic cancer progression in KrasG12D mice. In conclusion, we describe a novel mechanism by which GSK-3b fine-tunes NFATc2 and STAT3 transcriptional networks to integrate upstream signaling events that govern pancreatic cancer progression and growth. Furthermore, the therapeutic potential of GSK-3β is demonstrated for the first time in a relevant Kras and inflammation-induced GEMM for pancreatic cancer.

AB - We aimed to investigate the mechanistic, functional, and therapeutic role of glycogen synthase kinase 3β (GSK-3β) in the regulation and activation of the proinflammatory oncogenic transcription factor nuclear factor of activated T cells (NFATc2) in pancreatic cancer. IHC, qPCR, immunoblotting, immunofluorescence microscopy, and proliferation assays were used to analyze mouse and human tissues and cell lines. Protein-protein interactions and promoter regulation were analyzed by coimmunoprecipitation, DNA pulldown, reporter, and ChIP assays. Preclinical assays were performed using a variety of pancreatic cancer cells lines, xenografts, and a genetically engineered mouse model (GEMM). GSK-3β-dependent SP2 phosphorylationmediates NFATc2 protein stability in the nucleus of pancreatic cancer cells stimulating pancreatic cancer growth. In addition to protein stabilization, GSK-3β also maintains NFATc2 activation through a distinct mechanism involving stabilization of NFATc2-STAT3 complexes independent of SP2 phosphorylation. For NFATc2-STAT3 complex formation, GSK-3β-mediated phosphorylation of STAT3 at Y705 is required to stimulate euchromatin formation of NFAT target promoters, such as cyclin-dependent kinase-6, which promotes tumor growth. Finally, preclinical experiments suggest that targeting the NFATc2-STAT3-GSK-3β module inhibits proliferation and tumor growth and interferes with inflammationinduced pancreatic cancer progression in KrasG12D mice. In conclusion, we describe a novel mechanism by which GSK-3b fine-tunes NFATc2 and STAT3 transcriptional networks to integrate upstream signaling events that govern pancreatic cancer progression and growth. Furthermore, the therapeutic potential of GSK-3β is demonstrated for the first time in a relevant Kras and inflammation-induced GEMM for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84964317130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964317130&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0309

DO - 10.1158/1535-7163.MCT-15-0309

M3 - Article

C2 - 26823495

AN - SCOPUS:84964317130

VL - 15

SP - 491

EP - 502

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -